Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stemedica Cell Technologies (Stemedica), a provider of stem cell research and manufacturing, has filed an investigative new drug (IND) application with the FDA for clinical trial.
Subscribe to our email newsletter
The trial will assess the safety, tolerability and efficacy of Stemedica’s high potency allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
The proposed clinical trial will be a Phase I/II dose escalation and safety clinical trial using allogeneic mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke. The patient population will include individuals with functional or neurologic impairment related to the ischemic stroke that confines the subject to a wheelchair or requires the subject to have home nursing care or assistance with the general activities of daily living. The trial will take place at US medical centers.
Stemedica has been granted a license by the State of California’s Department of Public Health, Food and Drug Branch to manufacture stem cells for clinical trials in July, 2009. The drug manufacturing license grants the right to manufacture clinical-grade (for human use) drug or biologic products and recognises company as being compliant with California law and the applicable provisions of the Code of Federal Regulations.
Nikolai Tankovich, president and chief medical officer of Stemedica, said: “Stemedica achieved another milestone in its development program by moving from research to patient bedside to help people suffering from stroke. In addition to the official licensing of our manufacturing facility in San Diego, California, we have now established our own clinical trial pathway in compliance with FDA and FDB regulatory requirements. Stemedica’s goal is to receive regulatory approval of our mesenchymal stem cells for this clinical indication.”
Maynard Howe, vice chairman and CEO, said: “We are happy that Michael Levy, MD, PhD, Chief of Pediatric Neurosurgery at Rady Children’s Hospital of San Diego and Professor of Surgery at UCSD’s School of Medicine, will be the Principal Investigator leading our clinical trial.
“Stemedica is committed to developing, manufacturing and distributing adult stem cells that have the potential to save, restore and improve lives. This mission is central to everything that Stemedica does and we are dedicated to executing this mission with great passion and scientific discipline.”